Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

Abstract Background Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have been approved. In our institute, the CDx test for EGFR‐TKIs was changed from the Therascreen test (Therascreen) to the Cobas EGFR v2 test (Cobas) because only...

Full description

Bibliographic Details
Main Authors: Ken Uchibori, Natsuki Takano, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
Companion diagnostic (CDx)
EGFR mutation
EGFR‐TKI
next‐generation sequencing (NGS)
polymerase chain reaction (PCR)
Online Access:https://doi.org/10.1111/1759-7714.13797

Internet

https://doi.org/10.1111/1759-7714.13797

Similar Items